Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Eden Innovations Q1 FY27 Revenue Surges 152% as US Sales Momentum Accelerates
Highlights
US Operations Deliver Strong Quarterly Growth
Eden Innovations (ASX: EDE) announced a sharp acceleration in US revenue for the September 2026 quarter, supported by growth across both its OptiBlend and EdenCrete product portfolios.
Total Eden US revenue reached US$381,612, compared with US$151,237 in Q1 FY26. EdenCrete product sales increased 60% to US$121,749, while OptiBlend was the standout contributor, generating US$259,863 from kit sales and installation services across customers in Texas, Louisiana and Florida. The quarter also included Eden’s first OptiBlend export sale to Brazil.
OptiBlend Pipeline Builds Further Momentum
Beyond recognised revenue, Eden reported 19 new OptiBlend quotes during Q1 FY27 with a combined value of approximately US$1.07 million. This included 16 US opportunities valued at around US$916,000, alongside opportunities in Mexico and Bolivia.
The company also submitted an approximately US$249,000 OptiBlend quote connected with a generator supplier bidding to the US Army Corps of Engineers, while two installations worth approximately US$110,000 were planned for October 2026.
EdenCrete Pz7 Network Continues to Expand
Eden installed six new Pz7 bulk storage and dispensing systems at US ready-mix concrete plants during the quarter—three in Colorado, two in Texas and one in Minnesota. Another two installations were scheduled for October.
The expansion is important because each installation creates the potential for recurring product consumption as concrete plants progressively incorporate Pz7 into additional mixes.
Eden estimates that a fully utilised plant could eventually purchase approximately US$40,000–US$80,000 of Pz7 annually, although this remains an estimate based on historical sales experience rather than contracted revenue.
The chart on page 6 illustrates the rapid expansion of Eden’s bulk-dispensing footprint since 2024, with the network reaching 32 installed or pending locations across North and South America.
International Opportunities Add to Growth Pipeline
Eden is also pursuing opportunities beyond North America. Holcim’s nine Ecuador plants have generated cumulative Pz7 purchases exceeding US$697,830, while potential deployments are being reviewed in two additional South American countries. Trials are also continuing in the UK and France, while Eden reported encouraging trial results from its operations in India.
With OptiBlend demand strengthening and the EdenCrete installation network expanding, Eden believes its US business is positioned to deliver strong year-on-year revenue growth during FY27, subject to supportive market conditions.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au